Observational studyESC heart failure2023
Frailty interferes with the guideline-directed medical therapy in heart failure patients with reduced ejection fraction.
Observational study in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Survival benefit of guideline-directed medical therapy in older patients with heart failure: a systematic review and meta-analysis.Heart (British Cardiac Society) · 2026Pooled it
- Efficacy and Safety of Heart Failure Treatment According to Frailty Status: A Systematic Review.Journal of the American Heart Association · 2025Pooled it
- Benefit of cardiac resynchronization therapy among older patients: A patient-level meta-analysis.American heart journal · 2024Pooled it
- Optimizing cardiovascular pharmacotherapy in older adults with frailty.Nature reviews. Cardiology · 2026Review
- Mediation role of estimated pulse wave velocity in the association between physical activity and cognitive function.Medicine · 2026Article
- Multidimensional and Multidisciplinary Management of Heart Failure Patients with Frailty.Cardiac failure review · 2026Review
- Clinical Pharmacology of Heart Failure in Frailty.European cardiology · 2026Review
- Program theory and economic insights of a comprehensive geriatric assessment for frail heart failure patients.BMC geriatrics · 2025Article
- Impact of non-cardiovascular factors on cardiovascular death in acute decompensated heart failure: Enhancing predictive models with frailty and comorbid constipation-the Constipation and Frailty Augmented AHEAD score.Geriatrics & gerontology international · 2025Article
- Nutritional risk, frailty and functional status in elderly heart failure patients.ESC heart failure · 2025Article
- Adherence to Guideline-Directed Medical Therapy in Hospitalized Older People with Heart Failure at Discharge and 3-Month Follow-Up.Journal of clinical medicine · 2025Article
- Real-world use of guideline-directed therapy for heart failure: Insights from the Danish Heart Failure Registry.ESC heart failure · 2025Article
- Early Initiation of Guideline-Directed Medical Therapy Improves Outcomes in Heart Failure with Reduced Ejection Fraction Patients without Significant Risk of Nephrotoxicity.Acta Cardiologica Sinica · 2025Article
- Tolerability and Adverse Effects in a Specialized Heart Failure Guideline-Directed Medical Therapy Optimization Program.Clinical cardiology · 2025Article
- Novel predictors of infection-related rehospitalization in older patients with heart failure in Japan.Geriatrics & gerontology international · 2025Article
- The Hospital Frailty Risk Score as a Predictor of Mortality, Complications, and Resource Utilization in Heart Failure: Implications for Managing Critically Ill Patients.Biomedicines · 2025Article
- Heart Failure in Older Patients: An Update.Journal of clinical medicine · 2025Review
- Deprescribing strategies in older patients with heart failure.Internal and emergency medicine · 2025Review
- Sacubitril/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations).Heart failure reviews · 2025Review
- Prognostic impact of being underweight in patients undergoing mitral TEER: The OCEAN-Mitral registry.ESC heart failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
aimsGuideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF) is recommended in clinical guidelines, but elderly patients have not fully received GDMT in the clinical situation. The aim of this study was to determine the clinical characteristics of patients who have not received GDMT and the association between implementation of GDMT at discharge and physical frailty in patients with HFrEF who were hospitalized for acute decompensated heart failure (ADHF). METHODS AND
resultsThis study was a cross-sectional study with a retrospective analysis of the Kochi YOSACOI study, a prospective multicentre observational study that enrolled 1061 patients hospitalized for ADHF from May 2017 to December 2019 in Japan. Of 339 patients (32.0%) with HFrEF, 268 patients who were assessed for physical frailty by the Japanese version of the Cardiovascular Health Study criteria were divided into two groups: those with GDMT (135 patients, 50.4%) and those without GDMT (133 patients, 49.6%). GDMT was defined as the prescription of a combination of renin-angiotensin system (RAS) inhibitors (angiotensin-converting inhibitors or angiotensin receptor blockers) and beta-blockers. The median age of patients with HFrEF was 76 years (interquartile range, 67-83 years). Patients without GDMT were older than patients with GDMT (73 years vs. 78 years, P < 0.001). Patients without GDMT tended to have more prior HF admission than did patients with GDMT (P = 0.004), and patients without GDMT had lower levels of estimated glomerular filtration rate (P < 0.001) than those in patients with GDMT. Physical frailty was observed in 54.1% of the patients without GDMT and in 38.5% of the patients with GDMT (P = 0.014). Patients without GDMT had a higher rate of cognitive impairment than that in patients with GDMT (P = 0.009). RAS inhibitors only, beta-blockers only, and both RAS inhibitors and beta-blockers were less frequently prescribed in patients with physical frailty than in patients with physical non-frailty (52.0% vs. 86.7%, P < 0.05; 70.1% vs. 100.0%, P < 0.05; 42.5% vs. 86.7%, P < 0.01, respectively). In logistic regression analysis, compared with physical non-frailty, physical frailty was significantly associated with no implementation of GDMT (odds ratio: 6.900, 95% confidence interval: 1.420-33.600; P = 0.017), independent of older age and severe renal dysfunction.
conclusionsThe results of this study suggest that physical frailty is one of the factors that may withhold GDMT in patients with HFrEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.